Special issues when caring for the older person with acute coronary syndromes.
Persons 75 years of age or older constitute 6% of the US population but account for more than one third of those with acute coronary syndromes (ACS). Unfortunately, most randomized clinical trials have enrolled few older persons, and, as a result, few data are available to guide clinical practice. As in younger patients, aspirin, beta-blockers, nitrates, clopidogrel, heparin, statins, and angiotensin-converting enzyme inhibitors are useful, beginning with lower doses and carefully observing the patient for symptoms of toxicity. Similarly, older patients should not be denied the benefit of reperfusion therapy and early invasive strategy because of their age. Although primary angioplasty is an optimal reperfusion strategy, thrombolytic therapy is a beneficial alternative in carefully selected older patients. Although glycoprotein IIb/IIIa inhibitors appear to be beneficial in select cases, bleeding concerns exist. Despite a growing body of evidence in support of aggressive ACS care in older persons, evidence-based therapy is underused in older patients. Continued efforts are required to improve the quality of care to this high-risk cohort of ACS patients.
Shah
Rahman
R
Yale University School of Medicine, PO Box 208017, 333 Cedar Street, Room 315B FMP, New Haven, CT 06520-8025, USA. joanne.foody@yale.edu
Foody
JoAnne Micale
JM
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy*; D005853:Geriatrics; D006801:Humans; D009204:Myocardial Revascularization; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D017410:Practice Guidelines as Topic; D011379:Prognosis; D013577:Syndrome; D015912:Thrombolytic Therapy
D019039:Platelet Glycoprotein GPIIb-IIIa Complex